Scott Buzby , 2025-05-16 14:36:00
The WARRIOR trial compared intensive medical therapy with usual care in a cohort of women with suspected ischemia with nonobstructive coronary disease.
Read Healio’s in-depth coverage of the WARRIOR trial, including expert perspective.
Researchers enrolled 2,476 women with suspected ischemia with nonobstructive coronary disease (INOCA), defined by coronary angiography or coronary CTA, and randomly assigned them to intensive medical therapyor usual care follow-up every 6 months.
WARRIOR s the largest study of women with INOCA and the only trial with a major adverse CV outcome in this population.
At 5 years, the intensive strategy did not reduce risk for the primary composite outcome CV death, nonfatal MI, stroke, hospitalization for angina or hospitalization for HF.
The researchers s the COVID-19 pandemic, combined with the limitations of a pragmatic study design, had a large impact on the results and the data should not be interpreted as endorsing discontinuation of statins, ACE inhibitors or s for women with INOCA.
The WARRIOR trial was presented at the 2025 American College of Cardiology Scientific Session.
